Common Stock, $0.0001 par value per share
- Symbol
- ARTV
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Artiva Biotherapeutics, Inc.
ARTVNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.…
Press release in this filing
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights →Company context
Artiva is a clinical-stage biotechnology company that has focused on developing allogeneic natural killer (NK) cell therapies for autoimmune diseases. AlloNK® (AB-101), the Company’s lead development candidate, is a non-genetically modified, allogeneic, cryopreserved NK cell therapy that was evaluated in combination with B-cell-targeted monoclonal antibodies. On October 27, 2026, Artiva announced the discontinuation of further clinical development of AlloNK and the initiation of an evaluation of strategic alternatives. Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Current securities
Registered securities in this filing
Artiva Biotherapeutics, Inc. · 8-K · Filed 2026-08-06
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1.
The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, regardless of any general incorporation language in any such filing, unless Artiva expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
Filed exhibits (1)
EX-99.1 2 artv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient administration U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis (RA) Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients in the second half of 2026 Strong balance sheet with cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029 SAN DIEGO, August 6, 2026 -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced financial results for the second quarte…
Open exhibit ↗